Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4005104 | American Journal of Ophthalmology | 2007 | 10 Pages |
Abstract
Intravitreal bevacizumab causes ultrastructural changes in the choriocapillaris of primate eyes. A significant reduction of choriocapillaris endothelial cell fenestrations is seen as early as 24 hours after injection and their number increases again after two weeks. These findings may play a role in the early clinical effect of intravitreal bevacizumab for macular edema. Because an increased risk of circulation disturbances in the choriocapillaris cannot be excluded, patients should be carefully monitored.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Swaantje Peters, Peter Heiduschka, Sylvie Julien, Focke Ziemssen, Heike Fietz, Karl Ulrich Bartz-Schmidt, Tübingen Bevacizumab Study Group Tübingen Bevacizumab Study Group, Ulrich Schraermeyer,